The company states: “Acadia Pharmaceuticals announced that two oral presentations featuring DAYBUE findings in Rett syndrome will be presented at the American Academy of Neurology 2024 annual meeting, being held this week in Denver, CO. The presentations include outcomes from the DAFFODIL(TM), a Phase 2/3 open-label study evaluating the safety, tolerability and exploratory efficacy of DAYBUE in girls aged two to four living with Rett syndrome, as well as findings from exit interviews with caregivers of individuals living with Rett syndrome who participated in the LAVENDER(TM), LILAC(TM), LILAC-2(TM) and DAFFODIL studies.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Largest borrow rate increases among liquid names
- Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Acadia Pharmaceuticals price target lowered to $30 from $40 at Morgan Stanley
- Oracle, Dollar General upgraded: Wall Street’s top analyst calls